James Stocklasar Thomas Jr.
Contributor since: 2011
Latest Articles
Savvy Investors Discover Antares' Growing Revenue Stream
The Future Of Zalicus In 2013
Recalculating Celsion's Upcoming Results
Why Is Antares Rising So Quickly?
Why Growth Stock Antares Is Moving Higher
Celsion: The Heat Is On
Sizing Up Celsion's Odds Of Success
Why Celsion Is A Strong Buy On The Dip
Pre-HEAT Celsion Catalysts Confirm Strong Buy
A Reasoned Case For Celsion's ThermoDox
Cel-Sci: Immunotherapy Opens New Door To Investors
Buying Teva's Immunotherapy Investment
Top 5 Fiscal Cliff Biotech Buys
Smart Day Traders Ring The Register On Acadia And Zalicus
Why Cash Overrules The Momentary Market Bounce
Why I'm 'In Cash' For Biotechs In A Bearish Market
Acadia's Bubbling To Move Higher
Why Acadia May Be This Year's Holiday Prize
Time To Buy Housing Stocks Like DR Horton
How Sirius Could Grow Its Bottom Line
BioClinica: A Stealth Stock For Savvy Buyers?
Reconsidering Zalicus And Antares In Light Of Shakeups
A Reasoned Case For Pimavanserin's Success
Under Construction Rehash: Buy Acadia And Astex
More Evidence For Catalyst's Potential Vigabatrin Success
Buying Into Catalyst Pharma's Fast Tracked Vigabatrim On Friday
Zalicus Misses Key Secondary Endpoint
Astex's Linear Rise Versus Peregrine's And Cell Therapeutics' Sudden Pop
Bulls Keep Knocking On Astex's Door
Zalicus: When Push Comes To Shove
Early Thursday: Make Money On Zalicus, Why Not?
Going Into Monday Zalicus' S-3 Surprise